18 January 2018 (Thursday)

“The Oncologist” newsletter arrived in my in-box this morning:

The Oncologist Headerareaareaareaareaareaareaareaareaareaareaarea
Featured Article

Nadia Harbeck et al.

The biosimilar filgrastim EP2006 (Zarzio, Zarxio, biosimilar filgrastim‐sndz) has been approved in Europe since 2009 and in the U.S. since 2015. This combined analysis of two phase III studies provides additional clinical evidence that the biosimilar filgrastim EP2006 has a safety profile consistent with previous studies of reference filgrastim and supports large postmarketing studies of EP2006 in Europe. Strengthening the evidence for biosimilar filgrastim can help improve acceptance of biosimilars and increase patient access to biologics.
CME Activities

Male Breast Cancer as a Second Primary Cancer: Increased Risk Following Lymphoma

Predictors of Disruptions in Breast Cancer Care for Individuals with Schizophrenia

Clinical Trial Results

Lessons Learned

> Treatment with BEZ235 has not been shown to demonstrate increased efficacy compared with everolimus and may be associated with a poorer tolerability profile.

> The hypothesis of dual targeting of the phosphatidylinositol 3‐kinase and mammalian target of rapamycin pathways in patients with advanced pancreatic neuroendocrine tumors may warrant further study using other agents.
Best of Chabner Colloquium 2017

Watch exclusive interviews of our experts summarizing key points from the 2017 Chabner Colloquium Annual Meeting in Boston.

Session 1: New Insights into DNA Repair and Drug Response
Session 2: Targets That Defy Effective Therapy
Session 3: Promising Drug-antibody Conjugates and Cell Death Pathway Inhibitors

No comments:

Post a Comment